---
document_datetime: 2023-09-21 18:45:29
document_pages: 8
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/sonata-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: sonata-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.4577515
conversion_datetime: 2025-12-23 20:29:42.886605
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Sonata

<!-- image -->

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                         | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on no   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|------------------------------------------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/03140          | Periodic Safety Update EU Single assessment - ZALEPLON                                                                                                                                                                        | 26/03/2015                          | 27/05/2015                                     | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/03140.                                                                                                                                                    |
| II/0033              | Update of sections 4.5, 4.9 and 5.3 of the SmPC in order to update the safety information related to drug-drug interactions with diphenhydramine, fertility and overdose. The Package Leaflet is updated accordingly. product | 23/10/2014                          | 27/05/2015                                     | SmPC, Annex II, Labelling and PL | Diphenhydramine is reported to be a weak inhibitor of aldehyde oxidase in rat liver, but its inhibitory effects in human liver are not known. There is no pharmacokinetic interaction between zaleplon and diphenhydramine following the administration of a single dose (10 mg and 50 |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

edicinal product no longer authorise

<!-- image -->

<div style=\"page-break-after: always\"></div>

IG/0277

In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to bring the PI in line with the latest QRD template version 9.0.

C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data

C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation

<!-- image -->

26/03/2013

n/a

<!-- image -->

mg, respectively) of each drug. However, because both of these compounds have CNS effects, an additive pharmacodynamic effect is possible.

In a fertility and reproductive performance study in rats, mortality and decreased fertility were observed in males and females at an oral zaleplon dose of 100 mg/kg/day (equivalent to 49-times the maximum recommended human dose (MRHD) of 20 mg on a mg/m2 basis). Followup studies indicated that impaired fertility was due to an effect on the female.

In embryofetal development studies, oral administration of zaleplon up to 100 mg/kg/day and 50 mg/kg/day to pregnant rats and rabbits, respectively, produced no evidence of teratogenicity (equivalent to 49- (rat) and 48(rabbit) times the MRHD on a mg/m2 basis). Pre-and postnatal growth of rats was reduced at the maternally toxic dose of 100 mg/kg/day. The no-effect dose for growth of rat offspring was 10 mg/kg (equivalent to 5-times the MRHD on a mg/m2 basis). No adverse effects on embryofetal development were observed in rabbits.

In a pre- and postnatal development study in rats, increased stillbirth and postnatal mortality, and decreased growth and physical development, were observed in the offspring of females treated with doses of â‰¥7 mg/kg/day that did not elicit maternal toxicity. The no-effect dose for postnatal development was 1 mg/kg/day (equivalent to 0.5-times the MRHD on a mg/m2 basis). In a subsequent cross-fostering study, adverse effects on offspring viability and growth appeared to result from both in utero and lactational exposure to zaleplon.

edicinal product no longer authorise

<div style=\"page-break-after: always\"></div>

| II/0030   | Update version of the ASMF by the current active substance manufacturer to replace the site for micronizacion operation and testing for particle size of the micronized active susbstance and related changes. B.I.a.z - Change in manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 15/03/2012    | 15/03/2012                                         |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|----------------------------------------------------|
| II/0031/G | This was an application for a group of variations. to replace the current manufacturing site of the finished product by the new manufacturing site and related changes in the manufacturing process. B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging, for non-sterile medicinal products B.II.e.1.a.1 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Solid pharmaceutical forms B.II.b.3.b - Change in the manufacturing process of the finished product - Substantial changes to a manufacturing process that may have a significant impact on the quality, safety and efficacy of the medicinal product B.III.1.b.3 - Submission of a new or updated Ph. Eur. TSE Certificate of suitability - Updated certificate from an already approved manufacturer B.III.1.b.2 - Submission of a new or updated Ph. product | 15/12/2011 no | 06/02/2012 SmPC, Annex II, Labelling and PL longer |

<!-- image -->

edicinal product no longer authorise

<div style=\"page-break-after: always\"></div>

|         | a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer                                                                                                                                       |                    |            |                                         |                                                                                                                                                                                                                                                                                                                                                                                                     |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------|------------|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0027 | IA_07_b_01_Replacement/add. of manufacturing site: Primary packaging site - Solid forms IA_08_b_02_Change in BR/QC testing - repl./add. manuf. responsible for BR - incl. BC/testing                                                       | 29/06/2009         | n/a        | Annex II and PL                         |                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0028 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                                                   | 24/06/2009         | n/a        |                                         |                                                                                                                                                                                                                                                                                                                                                                                                     |
| R/0026  | Renewal of the marketing authorisation.                                                                                                                                                                                                    | 18/12/2008         | 19/02/2009 | SmPC, Annex II, Labelling and PL longer | Based on their review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP was of the opinion that the quality, safety and efficacy continue to be adequately and sufficiently demonstrated. Therefore, the benefit/risk profile of Sonata continues to be favourable. The Marketing Authorisation for Sonata is renewed with unlimited validity. |
| IA/0025 | IA_09_Deletion of manufacturing site                                                                                                                                                                                                       | 01/09/2008 product | n/a no     | Annex II and PL                         |                                                                                                                                                                                                                                                                                                                                                                                                     |
| IA/0024 | IA_47_c_Deletion of a pack size(s)                                                                                                                                                                                                         | 01/09/2008         | n/a        | SmPC, Annex II, Labelling and PL        |                                                                                                                                                                                                                                                                                                                                                                                                     |
| T/0023  | Transfer of Marketing Authorisation                                                                                                                                                                                                        | 15/11/2007         | 12/12/2007 | SmPC, Labelling and PL                  |                                                                                                                                                                                                                                                                                                                                                                                                     |
| II/0020 | Update of the section 4.4 (Special warnings and precautions for use) of the Summary of Product Characteristics (SPC) to include warnings regarding complex sleep-related behaviours and anaphylactic/anaphylactoid reactions (specifically | 18/10/2007         | 21/11/2007 | SmPC, Labelling and PL                  | The MAH performed a cumulative review of the post- marketing safety surveillance database up to March 2007. In this review, 12 reports suggestive of complex sleep behaviour were identified. They include cases of sleep- walking, sleep-driving and other complex behaviours such                                                                                                                 |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | section 4.8 (Undesirable effects) of the SPC and relevant sections of the Package Leaflet (PL) have been updated accordingly. Furthermore, changes to the labelling and Package Leaflet have been introduced, in accordance with the QRD template and the contact details for the local representative of Bulgaria and Romania has been included. Update of Summary of Product Characteristics, Labelling and Package Leaflet   | product no longer   | angioedema). Additionally,   |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|------------------------------|
| IA/0022 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.)                                                                                                                                                                                                                                                                                                                              | n/a                 |                              |
| IA/0021 | IA_04_Change in name and/or address of a manuf. of the active substance (no Ph. Eur. cert. avail.) IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                                                                                                                                                            | n/a                 |                              |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

| II/0019   | Update of Summary of Product Characteristics (section 4.4 Special Warnings and Special Precautions for Use) to include a specific warning on the potential for dependence with zaleplon. Corresponding changes have been introduced in section 2 of the Package Leaflet. Update of Summary of Product Characteristics, Labelling and Package Leaflet   | 27/04/2006   | 12/06/2006    | SmPC, Annex II, Labelling and PL longer   | In the 9th Periodic Safety Update Report (PSUR) for Sonata, 4 case reports of dependence were included. In view of this the CHMP requested the MAH to update the Product Information accordingly. Subsequently, the MAH identified in its database 14 reports consistent with dependence on zaleplon. Most of the patients were taking other psychotropic medications. Therefore, the following information has been included in the Summary of Product Characteristics: \"There have been post-marketing reports of dependence associated with zaleplon predominantly in combination with other psychotropic agents.\" The Package Leaflet was updated accordingly. In addition, in this Type II variation, the MAH updated the list of local representatives and updated the Product Information in accordance to the latest template.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------|-------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0018   | Update of sections 4.8 and 4.9 of the SPC and consequent changes of the PL following CHMP assessment of the PSUR 8. Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                   | 26/05/2005   | 04/07/2005 no | SmPC and PL                               | Section 4.8 (Undesirable effects) of the SPC was updated to reflect the available info on hepatotoxicity (mostly described as increased transaminase levels). In section 4.9 (Overdose), information was added that chromaturia (blue- green urine discolouration) has been reported in connection with zaleplon overdose.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| N/0017    | The Marketing Authorisation Holder (MAH) applied for the inclusion of additional local representatives of the MAH for all new Member States. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) product                                                                                                  | 09/06/2004   | n/a           | PL                                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| R/0016    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                | 21/01/2004   | 31/03/2004    | SmPC, Annex II, Labelling                 | The CHMP was of the opinion that the quality, safety and efficacy of Sonata continues to be adequately                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         |                                                                                                  |                    | and                        | PL demonstrated and therefore that the benefit/risk profile of Sonata remains favourable in the approved indication.   |
|---------|--------------------------------------------------------------------------------------------------|--------------------|----------------------------|------------------------------------------------------------------------------------------------------------------------|
| IA/0015 | IA_22_a_Submission of TSE Ph. Eur. certificate for exc. - Approved/new manufacturer              | 20/10/2003         | n/a                        |                                                                                                                        |
| II/0014 | Update of Summary of Product Characteristics and Package Leaflet                                 | 22/05/2003         | 16/09/2003 SmPC            | and PL                                                                                                                 |
| N/0013  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 17/02/2003         | 17/03/2003 PL              |                                                                                                                        |
| II/0012 | Update of Summary of Product Characteristics and Package Leaflet                                 | 27/06/2002         | 10/09/2002 SmPC and longer | PL                                                                                                                     |
| I/0010  | 20_Extension of shelf-life as foreseen at time of authorisation                                  | 28/09/2001 no      | 21/11/2001 SmPC            |                                                                                                                        |
| N/0011  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 19/11/2001         | 28/01/2002 PL              |                                                                                                                        |
| N/0009  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 25/04/2001 product | 14/06/2001 PL              |                                                                                                                        |
| II/0008 | Update of or change(s) to the pharmaceutical documentation                                       | 29/03/2001         | 05/04/2001                 |                                                                                                                        |
| II/0007 | Update of Summary of Product Characteristics and Package Leaflet                                 | 14/12/2000         | 20/03/2001 SmPC            | and PL                                                                                                                 |
| N/0006  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 12/04/2000         | 31/05/2000 Labelling PL    | and                                                                                                                    |

<!-- image -->

<div style=\"page-break-after: always\"></div>

| I/0005   | 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process   | 20/12/1999   | 09/03/2000 SmPC                    |
|----------|--------------------------------------------------------------------------------------------------|--------------|------------------------------------|
| I/0004   | 30_Change in pack size for a medicinal product                                                   | 20/12/1999   | 09/03/2000 SmPC,                   |
| I/0003   | 30_Change in pack size for a medicinal product                                                   | 20/12/1999   | 09/03/2000 SmPC,                   |
| I/0002   | 25_Change in test procedures of the medicinal product                                            | 29/04/1999   | 10/05/1999                         |
| I/0001   | 01_Change in the name of a manufacturer of the medicinal product                                 | 23/04/1999   | Labelling and PL 06/05/1999 longer |

edicinal product no longer authorise